Company Updates - Bolt Projects Holdings Inc (NASDAQ:BSLK) announced preliminary fiscal 2025 results and updated its fiscal 2026 guidance, raising its FY2026 sales guidance from $9.000 million to $11.000 million, with fourth-quarter sales projected at $2.700 million [1] - Shares of Bolt Projects Holdings rose 28.2% to $1.73 in pre-market trading following the announcement [1] Market Movements - Republic Power Group Limited (NASDAQ:RPGL) surged 81.4% to $0.4777 in pre-market trading [4] - Fitell Corp (NASDAQ:FTEL) rose 42.3% to $1.04 after announcing an interim dividend and shareholder loyalty program [4] - Antelope Enterprise Holdings Ltd (NASDAQ:AEHL) increased by 38% to $1.78 after a previous decline of 12% [4] - DigitalBridge Group Inc (NYSE:DBRG) gained 36.7% to $19.00 following reports of SoftBank nearing a deal for the company [4] - Davis Commodities Ltd (NASDAQ:DTCK) rose 16.8% to $0.46 after reporting revenue of $95 million for the six months ending June 30, up 42.1% from $66.9 million a year earlier [4] Other Notable Stocks - VolitionRX Ltd (NYSE:VNRX) rose 12.8% to $0.28, with a maintained Buy rating but a lowered price target from $5 to $3 by D. Boral Capital analyst Jason Kolbert [4] - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) rose 7.1% to $7.54 after submitting a Biologics License Application to the FDA for Imsidolimab [4]

Group 1: Market Overview - The Christmas week began with positive momentum from Big Tech, particularly driven by Nvidia's H200 chip, although gains were limited as traders sought safe-haven assets [1] - The U.S. economy showed stronger-than-expected growth at 4.3% for Q3, while durable goods orders fell by 2.2% in October [1] - The S&P 500 Index achieved a record close during the Christmas Eve session, and all three major indexes posted healthy weekly gains despite initial concerns about a "Santa Claus" rally [2] Group 2: Drug Industry Developments - Biohaven's treatment for major depressive disorder did not meet its primary objective in a phase 2 study, impacting its stock performance [3] - Novo Nordisk received FDA clearance for its GLP-1 pill, indicating a positive development for the company [3] - Vanda Pharmaceuticals is seeking approval for its antibody treatment for psoriasis, which could enhance its market position [3] Group 3: Technology Sector Highlights - Nvidia continues to attract bullish sentiment despite its stock's volatility, reflecting strong investor confidence [4] - Tesla reached new record highs, showcasing its ongoing growth and market interest [4] - Micron Technology extended its record-breaking performance, indicating robust demand in the semiconductor sector [4] Group 4: Upcoming Economic Reports - The upcoming week will feature key economic reports, including November's pending home sales and the minutes from the December FOMC meeting, which could influence market sentiment [5]

Core Viewpoint - Vanda Pharmaceuticals Inc. will participate in the J.P. Morgan Healthcare Conference on January 15, 2026, with a corporate presentation scheduled for 9:00 a.m. Pacific Time [1] Group 1: Conference Participation - The corporate presentation can be accessed live on Vanda's corporate website [2] - Investors are encouraged to register and prepare at least 15 minutes prior to the conference [2] - An archived version of the conference will be available on Vanda's website for approximately 30 days [2] Group 2: Company Overview - Vanda Pharmaceuticals Inc. is a leading global biopharmaceutical company focused on developing innovative therapies to meet high unmet medical needs [3] - The company aims to improve the lives of patients through its therapeutic innovations [3]

Core Insights - Several healthcare and biotech companies experienced significant stock price increases due to clinical updates, earnings results, and regulatory developments Company Summaries - Sensei Biotherapeutics Inc. (SNSE) saw a 62.9% increase to $17.20 after hours, following a 21.4% rise at the close. The company reported a narrower third-quarter net loss of $4.6 million compared to $7.3 million a year earlier, ending September with $25.0 million in cash and equivalents, down from $41.3 million at the end of 2024 [2] - Praxis Precision Medicines, Inc. (PRAX) advanced 24.8% to $237.10 after positive results from the EMBOLD study on relutrigine. The Data Monitoring Committee recommended stopping the study early for efficacy, and the company is targeting an NDA filing in early 2026 after aligning with the FDA [3] - The CooperCompanies, Inc. (COO) climbed 13.0% to $87.01, reporting fourth-quarter net income of $84.6 million, or $0.43 per share, down from $117.5 million, or $0.58 per share, last year. Revenue rose 4.6% to $1.065 billion, and the company issued guidance for first-quarter EPS of $1.02-$1.04 and revenue of $1.019-$1.030 billion [4] - Vanda Pharmaceuticals Inc. (VNDA) gained 7.5% to $5.59 after the FDA lifted a partial clinical hold on protocol VP-VLY-686-3403, allowing for increased dosing of tradipitant [5] - Cue Biopharma, Inc. (CUE) rose 7.8% to $0.60 after an exclusive in-licensing deal with ImmunoScape to advance Immuno-STAT molecules in oncology [6]

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from a previous plan [1][2]. Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1]. - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1]. - The repurchase may occur through open market transactions or other means, with the plan set to expire on March 31, 2026, and can be suspended or discontinued at any time [3]. Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2]. Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4]. - The company has out-licensed therapeutic antibodies, including a PD-1 antagonist to GSK and an IL-36R antagonist to Vanda Pharmaceuticals [4]. - AnaptysBio plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5].

Core Viewpoint - AnaptysBio, Inc. has authorized an amended Stock Repurchase Plan allowing for the repurchase of up to $100 million of its common stock, in addition to the remaining $6.4 million from the previous plan [1][2] Group 1: Stock Repurchase Plan - The amended Stock Repurchase Plan allows AnaptysBio to repurchase up to $100 million of its outstanding common stock, with $6.4 million remaining from the previous $75 million plan [1] - As of November 20, 2025, AnaptysBio has repurchased a total of 3,443,188 shares, representing 11.2% of shares outstanding before the initiation of the repurchase plan [1] - The new plan will expire on March 31, 2026, and the timing and number of shares repurchased will depend on market conditions and other factors [3] Group 2: Financial Position - AnaptysBio anticipates ending 2025 with approximately $300 million in cash, cash equivalents, and investments, which includes a one-time $75 million commercial sales milestone expected in Q4 2025 from GSK [2] Group 3: Company Overview - AnaptysBio is a clinical-stage biotechnology company focused on innovative immunology therapeutics for autoimmune and inflammatory diseases, with a pipeline that includes several candidates in various stages of clinical trials [4] - The company plans to separate its biopharma operations from its royalty assets by the end of 2026, allowing investors to align their investment strategies with each entity's objectives [5]

Core Insights - Vanda Pharmaceuticals has announced positive topline results from a clinical study of tradipitant, indicating its potential as a key adjunct in the over $50 billion global GLP-1 agonist market [1][4]. Study Results - The study showed that only 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% in the placebo group, achieving a 50% relative reduction (p=0.0016) [2][4]. - The secondary endpoint was also met, with 22.4% of the tradipitant group experiencing vomiting and significant nausea, versus 48.3% in the placebo group (p=0.0039) [2][4]. Safety Profile - Tradipitant exhibited a favorable safety profile, consistent with previous studies, with no new safety signals reported [3][4]. Market Implications - The efficacy of tradipitant in reducing nausea and vomiting could significantly improve adherence to GLP-1 agonist treatments, which currently face a 30-50% discontinuation rate due to gastrointestinal side effects [5][6]. - The global GLP-1 agonist market is projected to exceed $50 billion, highlighting the potential financial impact of tradipitant's success [4][5]. Future Development - Vanda plans to initiate a Phase III program for tradipitant in the first half of 2026, aiming for regulatory approval to address the unmet need in managing GLP-1 induced nausea and vomiting [7][9].

Core Insights - Monumental Sports & Entertainment (MSE) has partnered with Ticketmaster as a Founding Partner for its new arena in downtown Washington, D.C., aiming to enhance the live event experience through advanced technology and personalization [1][2] - The partnership is part of a broader $800 million+ transformation initiative for the arena, focusing on creating a seamless and immersive fan experience [2] Company Overview - MSE is recognized as one of America's leading integrated sports and entertainment companies, committed to delivering extraordinary experiences and community engagement [3] - Ticketmaster is the world's largest ticket marketplace, processing 600 million tickets annually across over 35 countries, and is part of Live Nation Entertainment [3] Partnership Details - The collaboration will integrate Ticketmaster's technology across MSE's ecosystem, enhancing operations for teams like the NHL's Washington Capitals and NBA's Washington Wizards [2] - Ticketmaster will also have a significant media presence through the Monumental Sports Network, providing brand visibility and engagement opportunities [2] Strategic Goals - The partnership aims to redefine the fan journey from entry to experience within the arena, ensuring a smarter and safer environment [2] - MSE's initiative is designed to revitalize downtown D.C. and position it as a global sports and entertainment destination, attracting millions of visitors annually [2]

Group 1 - Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is recognized as a speculative investment opportunity by Jim Cramer, who suggests it can be considered a "spec" stock [1] - The company focuses on developing therapies for sleep, neurological, psychiatric, and inflammatory disorders [1] - On August 28, Vanda announced that the U.S. FDA granted Orphan Drug Designation for VGT-1849B, a selective JAK2 inhibitor aimed at treating polycythemia vera, a rare blood disorder characterized by excessive red blood cell production [1] Group 2 - The article suggests that while VNDA has potential, certain AI stocks may offer greater upside potential and lower downside risk [2]

Group 1: Apollo Global Management - Apollo Global Management announced the acquisition of Eagle Creek Renewable Energy, enhancing its position in the U.S. hydroelectric power sector [1] - Apollo Global shares rose 1.6% to settle at $125.00 [5] Group 2: National Fuel Gas Company - National Fuel Gas Company is noted for its "consistency" and will release its fourth quarter and full year fiscal 2025 earnings results on November 5 [1] - National Fuel Gas shares fell 0.5% to close at $81.68 [5] Group 3: Main Street Capital Corporation - Truist Securities analyst maintained a Hold rating on Main Street Capital and lowered the price target from $64 to $60 [2] - Cramer advised against investing in Main Street Capital [2] - Main Street Capital shares slipped 0.3% to settle at $57.45 [5] Group 4: Cameco Corporation - Cramer recommended owning Cameco Corporation, which has received an Outperform rating from CLSA analyst with a price target of $102 [2] - Cameco shares gained 2.1% to close at $88.13 [5] Group 5: Vanda Pharmaceuticals Inc. - Vanda Pharmaceuticals is considered a "spec" by Cramer, with third quarter results expected on October 29 [3] - Vanda Pharmaceuticals shares gained 0.2% to close at $5.50 [5]